PACB at a glance
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB, SEC CIK 1299130) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported revenue of $160.0 million (up 3.9% from FY2024) and a net loss of $546.4 million. Diluted EPS was -$1.82.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) shares worth $307.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by ORDONEZ KATHY on November 17, 2026 of 18,595 shares at $1.78 per share.
- In the last 90 days, PACB insiders reported 0 open-market purchases ($0) and 2 open-market sales ($2.1M) on Form 4, a net sale of $2.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $160.0M
- +3.9% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$2.1M
- 13F holders
- 29 funds
- $307.4M · −3 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $40.6M, up 6% YoY from $38.4M, driven by product revenue and services growth
- Gross margin 33.2% vs 41.4% YoY, with gross profit down 15% to $13.5M
- Instrument revenue up 16% to $13.9M, while consumables revenue declined 2% to $20.1M
- Operating loss $37.0M, with operating margin negative 91.2% vs negative 101.1% YoY
- Cash and investments $199.4M vs $279.5M at December 31, 2025; operating cash use $117.9M
- Outlook: consumables growth expected, but funding constraints, memory costs and tariffs remain headwinds
Risk Factors
- New asset-disposition risk: January 30, 2026 sale retained pre-closing liabilities tied to short-read sequencing technologies
- New expense-reduction risk: third-quarter 2026 workforce reductions and development cuts may disrupt operations and produce higher-than-anticipated charges
- Regulatory risk: BIOSECURE Act limits certain Chinese biotechnology equipment and services, potentially disrupting supply and commercialization
- Near-term market risk: Revio and Vega adoption may lag as customers delay capital purchases amid uncertain academic and NIH funding
- Financial risk: September 30, 2026 debt included $200.0 million due 2029 and $441.0 million due 2030 amid negative operating cash flow
AI summary of the PACB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Up to $100 million ATM equity capacity, providing PACB flexible access to capital without a committed issuance
- Potential shareholder dilution, with issuance timing and volume controlled by the company
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CFO Jim Gibson stepped down November 3, 2026, creating executive finance-transition risk
- Gibson remains an advisor through March 31, 2027, retaining salary, 2026 bonus eligibility and equity vesting
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 results announced for quarter ended September 30, 2026
- Exhibit 99.1 contains the financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $40.6M, up from $38.4M, led by instrument revenue $13.2M versus $11.3M
- Consumables revenue fell to $20.8M from $21.3M, while annualized Revio pull-through declined to ~$204,000 from ~$236,000
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Mark Van Oene becomes CEO and director August 5, succeeding Christian Henry, who remains on the Board
- CEO compensation: $743,000 salary, 100% target bonus, $1.6875M option, and $562,500 RSU award
Item EX-99.1: Item EX-99.1
- Q2 revenue $39.0M, down from $39.8M; consumables rose to $20.1M while instrument revenue declined to $12.8M
- Revio placements increased to 20 from 15, but Vega placements fell to 26 from 38 and annualized Revio pull-through declined to ~$202,000
Item 7.01: Regulation FD Disclosure
- August 5, 2026 press release announces leadership changes described under Item 5.02
- Leadership transition may affect PACB’s strategic execution and investor assessment of management continuity
Item 2.05: Costs Associated with Exit or Disposal Activities
- Workforce reduction of approximately 40 employees, or 8% of staff
- Annualized operating expense savings targeted at $30 million to $40 million by end-2027
Item EX-99.2: Item EX-99.2
- Mark Van Oene appointed President and CEO effective August 5, 2026, succeeding Christian Henry after six years
- Internal succession: Van Oene previously served as COO since 2021, reducing near-term leadership disruption risk
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026 announced
- Full financial results and management commentary available in Exhibit 99.1
AI summaries of PACB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PACB
Don't miss the next PACB filing
- Alerts as it files. A push when PACB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PACB, by share count.
- Ask anything. An AI agent that reads every PACB filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MEYER WILLIAM | A | Nov 17, 2026 | 72,309 | - |
| ORDONEZ KATHY | Sell | Nov 17, 2026 | 18,595 | $1.78 |
| MEYER WILLIAM | A | Nov 17, 2026 | 54,945 | - |
| Gibson James R II | M | Oct 6, 2026 | 500,000 | - |
| Gibson James R II | M | Oct 6, 2026 | 500,000 | $1.18 |
| Gibson James R II | Sell | Oct 6, 2026 | 661,815 | $3.11 |
| Van Oene Mark | Sell | Aug 17, 2026 | 26,911 | $1.13 |
| Van Oene Mark | A | Aug 10, 2026 | 1,967,888 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $200.5M | $154.0M | $160.0M |
| Gross Profit | - | $37.3M | $45.8M |
| Operating Income | - | -$474.3M | -$553.9M |
| Net Income | - | -$309.9M | -$546.4M |
| Gross Margin | - | 24.2% | 28.6% |
| Op. Margin | - | -308.0% | -346.2% |
| Net Margin | - | -201.2% | -341.5% |
| Balance Sheet | |||
| Total Assets | - | $1.3B | $784.1M |
| Equity | $701.3M | $506.6M | $5.3M |
| ROE | - | -61.2% | -10214.5% |
| Per Share | |||
| EPS | - | $-1.59 | $-1.82 |
| Cash Flow | |||
| Operating CF | - | -$206.1M | -$111.2M |
| CapEx | - | $6.2M | $2.7M |
Source: XBRL data in PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PACB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $307.4M |
| Q2 2026 | 32 | $190.0M |
| Q1 2026 | 30 | $146.2M |
| Q4 2025 | 28 | $213.8M |
| Q3 2025 | 29 | $118.9M |
| Q2 2025 | 28 | $111.4M |
| Q1 2025 | 27 | $88.7M |
| Q4 2024 | 21 | $161.7M |
- T. Rowe Price Group+10.70M (+4616%)
- Citadel Advisors LLC+3.67M (+129%)
- D.E. Shaw & Co+2.78M (+66%)
- Bank of America Corp+1.05M (+78%)
- Morgan Stanley+909.8K (+190%)
- AQR Capital Management−1.19M (-92%)
- Dimensional Fund Advisors−418.4K (-55%)
- Millennium Management−208.6K (-5%)
- Two Sigma Investments−204.5K (-5%)
- Wells Fargo & Co−170.7K (-60%)
- StoneX Group Inc.+15.3K
- Renaissance Technologies LLC−966.2K
- M&T Bank−26.7K
- FMR LLC (Fidelity)−25.3K
- PNC Financial Services−23
Source: 13F-HR filings on SEC EDGAR (aggregated from 224 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PACB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Jul 9, 2026 | - | Analysis | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 10-Q | May 8, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Apr 10, 2026 | - | - | - |
| 4 | Apr 3, 2026 | - | - | - |
| 8-K | Mar 6, 2026 | - | Analysis | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
PACB SEC filings: frequently asked questions
Are PACB insiders buying or selling?
In the last 90 days, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $2.1 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PACB stock?
As of September 30, 2026, the largest PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) holders among the 13F filers tracked by SignalX were BlackRock ($77.7 million), ARK Investment Management ($70.5 million), Vanguard Capital Management LLC ($31.4 million), T. Rowe Price Group ($25.9 million), D.E. Shaw & Co ($16.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PACB's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported revenue of $160.0 million (up 3.9% from FY2024) and a net loss of $546.4 million. Diluted EPS was -$1.82. The figures come from the XBRL data in the 10-K.
What did PACB report in its latest 8-K?
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an 8-K on November 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Up to $100 million ATM equity capacity, providing PACB flexible access to capital without a committed issuance.
What are the latest PACB SEC filings?
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 19, 2026.
What is PACB's SEC CIK number?
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)'s SEC Central Index Key (CIK) is 1299130. EDGAR lists every PACB filing under that number.
Ask anything about PACB
The research agent reads PACB's filings, financials, insider trades and 13F holders, then answers with sources.